These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24458223)

  • 21. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
    Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
    BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia.
    McEvoy C; Micek ST; Reichley RM; Kan J; Hoban A; Hoffmann J; Shorr AF; Kollef MH
    Surg Infect (Larchmt); 2014 Jun; 15(3):283-9. PubMed ID: 24801126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
    Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
    Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
    Stahl JE; Barza M; DesJardin J; Martin R; Eckman MH
    Arch Intern Med; 1999 Nov; 159(21):2576-80. PubMed ID: 10573047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
    BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality.
    Restrepo MI; Mortensen EM; Rello J; Brody J; Anzueto A
    Chest; 2010 Mar; 137(3):552-7. PubMed ID: 19880910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia.
    Burgess DS; Lewis JS
    Clin Ther; 2000 Jul; 22(7):872-8. PubMed ID: 10945513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.
    Arnold FW; Wiemken TL; Peyrani P; Ramirez JA; Brock GN;
    Respir Med; 2013 Jul; 107(7):1101-11. PubMed ID: 23660396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.
    Tumbarello M; De Pascale G; Trecarichi EM; Spanu T; Antonicelli F; Maviglia R; Pennisi MA; Bello G; Antonelli M
    Intensive Care Med; 2013 Apr; 39(4):682-92. PubMed ID: 23370828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].
    Karaboğa B; Çilli A
    Tuberk Toraks; 2015 Jun; 63(2):94-101. PubMed ID: 26167966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Features, Diagnostics, Etiology, and Outcomes of Hospitalized Solid Organ Recipients With Community-Acquired Pneumonia: A Retrospective Cohort Analysis.
    Joean O; von Eynern LP; Welte T; Einecke G; Dettmer S; Fuge J; Taubert R; Wedemeyer H; Rademacher J
    Chest; 2024 Oct; 166(4):697-707. PubMed ID: 38823578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.
    König R; Cao X; Oswald M; Forstner C; Rohde G; Rupp J; Witzenrath M; Welte T; Kolditz M; Pletz M;
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31537702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ventilator-associated pneumonia due to Pseudomonas aeruginosa.
    Crouch Brewer S; Wunderink RG; Jones CB; Leeper KV
    Chest; 1996 Apr; 109(4):1019-29. PubMed ID: 8635325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.
    Restrepo MI; Mortensen EM; Waterer GW; Wunderink RG; Coalson JJ; Anzueto A
    Eur Respir J; 2009 Jan; 33(1):153-9. PubMed ID: 18768577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.